Lilly, Incyte Data Show 'Significant Effect' by Baricitinib on Covid-19 Recovery
October 08 2020 - 12:22PM
Dow Jones News
By Josh Beckerman
Eli Lilly & Co. and Incyte Corp. have provided additional
data on baricitinib that indicates the drug has a "significant
effect" on recovery time for Covid-19 patients.
The companies said baricitinib in combination with remdesivir
reduced recovery time and improved clinical outcomes compared with
remdesivir in the ACTT-2 trial. The drug had the most impact on
patients requiring oxygen.
The companies, which previously said ACTT-2 met its primary
endpoint, shared additional data during a virtual conference.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 08, 2020 13:07 ET (17:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2024 to May 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From May 2023 to May 2024